Tirzepatide: Label Dosing, Evidence Hierarchy & Research Context (2026)

Tirzepatide is a dual GIP/GLP-1 agonist approved as a medicine. Dose escalation and contraindications are defined in label text and trial protocols. Independent peptide calculators should not be treated as clinical decision tools for prescription products.

Evidence hierarchy

Start with the approved label, then pivotal trial publications, then registry entries for ongoing studies. That ordering keeps dosing context anchored to verified regulatory facts. For the investigational triple agonist in the same class, see our retatrutide page; for the single GLP-1 analogue, see semaglutide.